BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31646809)

  • 21. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
    Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
    World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival.
    Kim HR; Seo M; Nah YW; Park HW; Park SH
    Nucl Med Commun; 2018 Jul; 39(7):691-698. PubMed ID: 29893751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration in pancreatic lesions.
    Wu QM; Guo YN; Xu YQ
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1397-1401. PubMed ID: 29565499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
    Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
    Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
    Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
    Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of FDG-PET scan in the diagnosis of pancreatic carcinoma].
    Papós M; Takács T; Pávics L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Trón L
    Orv Hetil; 2002 May; 143(21 Suppl 3):1283-6. PubMed ID: 12077917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Benefit of PET/CT in the preoperative staging in pancreatic carcinomas].
    Kysucan J; Lovecek M; Klos D; Tozzi I; Koranda P; Buriánková E; Neoral C; Havlík R
    Rozhl Chir; 2010 Aug; 89(7):433-40. PubMed ID: 20925260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy.
    DelMaschio A; Vanzulli A; Sironi S; Castrucci M; Mellone R; Staudacher C; Carlucci M; Zerbi A; Parolini D; Faravelli A
    Radiology; 1991 Jan; 178(1):95-9. PubMed ID: 1984331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT.
    Yoneyama T; Tateishi U; Endo I; Inoue T
    Eur J Radiol; 2014 Oct; 83(10):1734-9. PubMed ID: 25043494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
    Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
    Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.
    Rijkers AP; Valkema R; Duivenvoorden HJ; van Eijck CH
    Eur J Surg Oncol; 2014 Jul; 40(7):794-804. PubMed ID: 24755095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
    Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
    JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
    Saif MW; Cornfeld D; Modarresifar H; Ojha B
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
    Schima W; Függer R; Schober E; Oettl C; Wamser P; Grabenwöger F; Ryan JM; Novacek G
    AJR Am J Roentgenol; 2002 Sep; 179(3):717-24. PubMed ID: 12185052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.
    Diederichs CG; Staib L; Vogel J; Glasbrenner B; Glatting G; Brambs HJ; Beger HG; Reske SN
    Pancreas; 2000 Mar; 20(2):109-16. PubMed ID: 10707924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.